Mainz Biomed (MYNZ) announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz, the development bank of the German federal state of Rheinland-Pfalz. Under the ISB’s Innovation and Technology Support Program, the state will fund up to 50% of the project’s total costs. This direct governmental support represents a strong endorsement of the scientific and societal value of Mainz Biomed’s non-invasive, blood-based screening test for the early detection of pancreatic cancer and will accelerate its development.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Promising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy Rating
- Mainz initiates feasibility study of biomarker panel in PancAlert project
- Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting
- Mainz Biomed N.V. Secures $4 Million Through Securities Offering
- Mainz Biomed prices $4.0M offering of common stock at $2.00 per unit